Abstract
Objectives
For patients with differentiated thyroid carcinoma (DTC), distant metastases are commonly identified in the lungs and bones. However, they are relatively rare in other distant organs, such as the liver, kidneys, or brain. The aim of the current study was to describe the clinical outcomes and evaluate the prognostic factors of patients with no less than three different distant organ system metastases from DTC.
Methods
This study retrospectively identified 717 patients diagnosed with DTC with distant metastases between January 2005 and December 2017. Patient response to radioactive iodine (RAI) therapy was monitored by changes in serum thyroglobulin levels and imaging changes. Five-year and 10-year overall survival (OS) rates were calculated by the Kaplan–Meier methods and Cox proportional hazards.
Results
Among the 717 participants, 37 (5.16%) patients had no less than three different distant organ system metastases from DTC. Five-year and 10-year OS were 45.9% and 37.8% in patients with three or more distant organ system metastases while 74.5% and 64.9% in individuals with one or two distant organ system metastases, respectively. RAI avidity and RAIR-DTC were main independent prognostic factors influencing the clinical outcomes for both groups of patients. The presence of 3 or more different distant organ system metastases was the only independent prognostic factors for 10-year OS by multivariate analysis.
Conclusions
Patients with no less than three distant organ system metastases from DTC had poor prognosis. RAI avidity and RAIR-DTC were main factors influencing overall survival for patients with distant metastases from DTC in both groups.
Similar content being viewed by others
References
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018). https://doi.org/10.3322/caac.21442
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. (2018). https://doi.org/10.3322/caac.21492
C.M. Kitahara, J.A. Sosa, The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12(11), 646–653 (2016). https://doi.org/10.1038/nrendo.2016.110
L. Furuya-Kanamori, A. Sedrakyan, A.A. Onitilo, N. Bagheri, P. Glasziou, S.A.R. Doi, Differentiated thyroid cancer: millions spent with no tangible gain? Endocr. Relat. Cancer 25(1), 51–57 (2018). https://doi.org/10.1530/ERC-17-0397
S.Y. Sohn, H.I. Kim, Y.N. Kim, T.H. Kim, S.W. Kim, J.H. Chung, Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up. Clin. Endocrinol. 88(2), 318–326 (2018). https://doi.org/10.1111/cen.13489
P. Choksi, M. Papaleontiou, C. Guo, F. Worden, M. Banerjee, M. Haymart, Skeletal complications and mortality in thyroid cancer: a population-based study. J. Clin. Endocrinol. Metab. 102(4), 1254–1260 (2017). https://doi.org/10.1210/jc.2016-3906
A.B. Sheikh, A. Akhtar, U. Tariq, A.A.E. Sheikh, F.S. Siddiqui, M.M. Bukhari, Skull metastasis extending to the superior sagittal sinus: an unfamiliar presentation of papillary thyroid carcinoma. Cureus 10(6), e2738 (2018). https://doi.org/10.7759/cureus.2738
H.J. Song, Z.L. Qiu, C.T. Shen, W.J. Wei, Q.Y. Luo, Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur. J. Endocrinol. 173(3), 399–408 (2015). https://doi.org/10.1530/EJE-15-0296
Q.Y. Luo, Q. Luo, L.B. Chen, Y.L. Yu, H.K. Lu, R.S. Zhu, Multiple subdermal metastases from papillary thyroid cancer. Thyroid 18(8), 907–908 (2008). https://doi.org/10.1089/thy.2007.0181
L.Y. Wang, F.L. Palmer, I.J. Nixon, D. Thomas, S.G. Patel, A.R. Shaha, J.P. Shah, R.M. Tuttle, I. Ganly, Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. Thyroid 24(11), 1594–1599 (2014). https://doi.org/10.1089/thy.2014.0173
M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388(10061), 2783–2795 (2016). https://doi.org/10.1016/S0140-6736(16)30172-6
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020
H.G. Vuong, U.N.P. Duong, T.Q. Pham, H.M. Tran, N. Oishi, K. Mochizuki, T. Nakazawa, L. Hassell, R. Katoh, T. Kondo, Clinicopathological risk factors for distant metastasis in differentiated thyroid carcinoma: a meta-analysis. World J. Surg. 42(4), 1005–1017 (2018). https://doi.org/10.1007/s00268-017-4206-1
H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. J. Am. Med. Assoc. 317(13), 1338–1348 (2017). https://doi.org/10.1001/jama.2017.2719
C.A. Benbassat, S. Mechlis-Frish, D. Hirsch, Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J. Surg. 30(6), 1088–1095 (2006). https://doi.org/10.1007/s00268-005-0472-4
D. Casara, D. Rubello, G. Saladini, G. Masarotto, A. Favero, M.E. Girelli, B. Busnardo, Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J. Nucl. Med. 34(10), 1626–1631 (1993)
B.H. Lang, K.P. Wong, C.Y. Cheung, K.Y. Wan, C.Y. Lo, Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann. Surg. Oncol. 20(4), 1329–1335 (2013). https://doi.org/10.1245/s10434-012-2711-x
Y. Saito, K. Sugino, H. Takami, K. Matsuzu, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, H. Kawakubo, K. Ito, Y. Kitagawa. Clinical status and treatment of liver metastasis of differentiated thyroid cancer using tyrosine kinase inhibitors. World J. Surg. (2018). https://doi.org/10.1007/s00268-018-4676-9
A.R. Shaha, J.P. Shah, T.R. Loree, Differentiated thyroid cancer presenting initially with distant metastasis. Am. J. Surg. 174(5), 474–476 (1997)
M. Davidson, R.J. Olsen, A.A. Ewton, R.J. Robbins, Pancreas metastases from papillary thyroid carcinoma: a review of the literature. Endocr. Pract. 23(12), 1425–1429 (2017). https://doi.org/10.4158/EP-2017-0001
Y.W. Hong, J.D. Lin, M.C. Yu, C.C. Hsu, Y.S. Lin, Outcomes and prognostic factors in thyroid cancer patients with cranial metastases: a retrospective cohort study of 4,683 patients. Int J. Surg. 55, 182–187 (2018). https://doi.org/10.1016/j.ijsu.2018.06.001
K. Korhonen, H. Zhuang, Pediatric patient with cerebral metastasis from papillary thyroid cancer. Clin. Nucl. Med. 43(6), 471–473 (2018). https://doi.org/10.1097/RLU.0000000000002093
D. Albano, M.B. Panarotto, R. Durmo, C. Rodella, F. Bertagna, R. Giubbini, Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer. Endocrine 63(1), 79–86 (2019). https://doi.org/10.1007/s12020-018-1713-2
M.C. Kreissl, M.J.R. Janssen, J. Nagarajah, Current treatment strategies in metastasized differentiated thyroid cancer. J. Nucl. Med. 60(1), 9–15 (2019). https://doi.org/10.2967/jnumed.117.190819
H. Kim, H.I. Kim, S.W. Kim, J. Jung, M.J. Jeon, W.G. Kim, T.Y. Kim, H.K. Kim, H.C. Kang, J.M. Han, Y.Y. Cho, T.H. Kim, J.H. Chung, Prognosis of differentiated thyroid carcinoma with initial distant metastasis: a multicenter study in Korea. Endocrinol. Metab. 33(2), 287–295 (2018). https://doi.org/10.3803/EnM.2018.33.2.287
J.D. Lin, S.F. Kuo, B.Y. Huang, S.F. Lin, S.T. Chen, The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. Nucl. Med Commun. 39(12), 1091–1096 (2018). https://doi.org/10.1097/MNM.0000000000000897
N.D. Perrier, J.D. Brierley, R.M. Tuttle, Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 68(1), 55–63 (2018). https://doi.org/10.3322/caac.21439
G. Mazziotti, A.M. Formenti, M.B. Panarotto, E. Arvat, A. Chiti, A. Cuocolo, M.E. Dottorini, C. Durante, L. Agate, S. Filetti, F. Felicetti, A. Filice, L. Pace, T. Pellegrino, M. Rodari, M. Salvatori, C. Tranfaglia, A. Versari, D. Viola, S. Frara, A. Berruti, A. Giustina, R. Giubbini, Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Endocrine 59(1), 90–101 (2018). https://doi.org/10.1007/s12020-017-1455-6
D.H. Shah, A.M. Samuel, Metastasis to the liver in well-differentiated carcinoma of the thyroid. Thyroid 6(6), 607–611 (1996). https://doi.org/10.1089/thy.1996.6.607
C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892–2899 (2006). https://doi.org/10.1210/jc.2005-2838
P.M. Manohar, L.J. Beesley, E.L. Bellile, F.P. Worden, A.M. Avram, Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer. Clin. Nucl. Med. 43(9), 641–647 (2018). https://doi.org/10.1097/RLU.0000000000002193
M. Schlumberger, C. Challeton, F. De Vathaire, J.P. Travagli, P. Gardet, J.D. Lumbroso, C. Francese, F. Fontaine, M. Ricard, C. Parmentier, Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37(4), 598–605 (1996)
Z.L. Qiu, H.J. Song, Y.H. Xu, Q.Y. Luo, Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96(10), 3078–3086 (2011). https://doi.org/10.1210/jc.2011-0093
Acknowledgements
The authors thank the American Journal Experts for their help with the edition for proper English language, grammar, punctuation, spelling, and overall style by one or more of the highly qualified native English-speaking editors for this paper. This study was supported by the National Natural Science Foundation of China (Grant number 81671712) and the Shanghai Key Discipline of Medical Imaging (Grant number 2017ZZ02005).
Author contributions
X.Y.Z. and Z.L.Q. designed the study. X.Y.C. and J.W.S. conducted the statistical analysis. Y.W. collected the clinical data. X.Y.Z. wrote the whole paper. J.H.Z. and Q.Y.L. supervised and edited the paper. All authors read and approved the final paper.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, XY., Sun, JW., Qiu, ZL. et al. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma. Endocrine 66, 254–265 (2019). https://doi.org/10.1007/s12020-019-01999-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-01999-6